<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ATP-competitive mTOR kinase inhibitors (mTorKIs) are a new generation of mTOR-targeted agents with more potent anticancer activity than <z:chebi fb="0" ids="9168">rapamycin</z:chebi> in several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models </plain></SENT>
<SENT sid="1" pm="."><plain>However, the sensitivity and resistance of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells to mTorKIs remain poorly understood </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we tested mTorKIs against a large panel of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cell lines, and found that mTorKIs displayed broader anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> activity than <z:chebi fb="0" ids="9168">rapamycin</z:chebi>, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells with K-Ras or B-Raf mutations, suggesting that these mTorKIs are particularly useful for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> resistant to EGFR inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>Unexpectedly, we found that 40% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were intrinsically drug resistant </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, we discovered an mTOR-independent 4Eâ€‘BP1 phosphorylation that was correlated with mTorKI resistance </plain></SENT>
<SENT sid="5" pm="."><plain>Altogether, our findings provide compelling preclinical support for testing mTorKIs in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> clinical trials </plain></SENT>
<SENT sid="6" pm="."><plain>They further reveal the existence of significant intrinsic mTorKI drug resistance in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and suggest that 4E-BP1 phosphorylation is a predictive biomarker for mTorKI sensitivity and resistance </plain></SENT>
</text></document>